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Caspase 2 was initially identiﬁed as a neuronally expressed de-
velopmentally down-regulated gene (HUGO gene nomenclature
CASP2) and has been shown to be required for neuronal death
induced by several stimuli, including NGF (nerve growth factor)
deprivation and Aβ (β-amyloid). In non-neuronal cells the
PIDDosome, composed of caspase 2 and two death adaptor
proteins, PIDD (p53-inducible protein with a death domain)
and RAIDD {RIP (receptor-interacting protein)-associated
ICH-1 [ICE (interleukin-1β-converting enzyme)/CED-3 (cell-
deathdetermining3)homologue1]proteinwithadeathdomain},
has been proposed as the caspase 2 activation complex, although
the absolute requirement for the PIDDosome is not clear. To
investigate the requirement for the PIDDosome in caspase-2-
dependent neuronal death, we have examined the necessity for
each component in induction of active caspase 2 and in execution
of caspase-2-dependent neuronal death. We ﬁnd that both NGF
deprivation and Aβ treatment of neurons induce active caspase
2 and that induction of this activity depends on expression of
RAIDD, but is independent of PIDD expression. We show that
treatment of wild-type or PIDD-null neurons with Aβ or NGF
deprivation induces formation of a complex of caspase 2 and
RAIDD. We also show that caspase-2-dependent execution of
neurons requires RAIDD, not PIDD. Caspase 2 activity can be
inducedinneuronsfromPIDD-nullmice,andNGFdeprivationor
Aβ use caspase 2 and RAIDD to execute death of these neurons.
Key words: β-amyloid, hippocampal neuron, nerve growth factor
deprivation, neuronal death, Penetratin1 small-interfering RNA
(Pen1-siRNA), PIDDosome, sympathetic neuron.
INTRODUCTION
Althoughcaspase2wasthesecondmammaliancaspaseidentiﬁed
[1,2] much remains to be discovered regarding the regulation
and function of this caspase. The initial identiﬁcation in mouse
was by a screen of NEDD (neural-precursor-cell-expressed
developmentally down-regulated) genes, suggesting a role for
caspase 2 in neuronal development [1]. This role was not
substantiated in caspase 2-null mice, which had grossly normal
neuronal development [3], but we have shown that these mice
had an increase in caspase 9 and Smac (second mitochondrial-
derived activator of caspase)/DIABLO [direct IAP (inhibitor of
apoptosis)-binding protein with low pI] in the nervous system,
providing a potential compensation for loss of caspase 2 [4].
Our previous studies of neuronal death in primary neuronal
cultures have shown that caspase 2 is required for death
induced by Aβ (β-amyloid) or by NGF (nerve growth factor)
deprivation in wild-type neurons [4–6]. Structurally caspase
2 resembles other initiator caspases, with a long pro-domain
which contains a CARD (caspase-recruitment domain) sequence,
similar to caspase 9, DRONC (Drosophila Nedd2-like caspase)
and CED-3 (cell-death determining 3) [7]. Caspases with long
pro-domains are activated by proximity-induced dimerization;
at endogenous caspase levels dimerization is facilitated by
adaptor proteins, such as Apaf-1 (apoptotic protease-activating
factor 1) for caspase 9 and ced-4 for ced-3 [8]. For caspase
2 RAIDD {RIP (receptor-interacting protein)-associated ICH-1
[ICE (interleukin-1β-converting enzyme)/CED-3 homologue 1]
protein with a DD (death domain)} has been identiﬁed as a
speciﬁc adaptor protein and shown to interact via CARD with
caspase 2 [9]. RAIDD was found to interact via its DD with
RIP1K (RIP kinase 1), but a role for a caspase 2–RAIDD–RIP1K
complex was never conﬁrmed. Subsequent studies have shown
that RAIDD can interact with the DD-containing protein PIDD
(p53-inducible protein with a DD) via the DD. The PIDDosome,
composed of PIDD, RAIDD and caspase 2, was proposed as the
activation platform for caspase 2 [10]. This complex was shown
to form spontaneously in cell extracts subjected to a temperature
shift.PIDD-nullmicehavebeengenerated,andnon-neuronalcells
were studied for the response to DNA damage and PIDD was not
required [11,12]. Caspase 2 activity was not measured in those
studies, but formation of a caspase 2-containing large-molecular-
mass complex upon temperature shift was shown to occur
independent of PIDD or RAIDD [11]. We have previously shown
that RAIDD is required for NGF-deprivation-mediated death of
primaryculturesofsympatheticneurons[13];thisdeathparadigm
requires caspase 2 [4]. We have also shown that, although DNA-
damage-mediated neuronal death is caspase-dependent [14],
RAIDD is not required for this death [13]. We now examine
the requirement for the PIDDosome in caspase 2 activation
and the execution of caspase-2-mediated neuronal death,
speciﬁcallydeathinducedbyAβ orbyNGFdeprivation.Weshow
thatcaspase2canbeactivatedandmediatedeathintheabsenceof
PIDD,butnotintheabsenceofRAIDD.WefurthershowthatAβ
treatment and NGF deprivation induce formation of a complex of
caspase 2 and RAIDD in wild-type and PIDD-null neurons.
Abbreviations used: Aβ, β-amyloid; AS, antisense; biotin-VAD-FMK, biotin-Val-Ala-DL-Asp-ﬂuoromethylketone; CARD, caspase-recruitment domain;
CED-3, cell-death determining 3; DD, death domain; ERK, extracellular-signal-regulated kinase; HFIP, 1,1,1,3,3,3 hexaﬂuoro-2-propanol; NGF, nerve
growth factor; P1, postnatal day 1; Pen1, Penetratin1; PIDD, p53-inducible protein with a death domain; RAIDD, RIP (receptor-interacting protein)-
associated ICH-1 [ICE (interleukin-1β-converting enzyme)/CED-3 homologue 1] protein with a DD; RIP, receptor-interacting protein; RIP1K, RIP kinase 1;
SCG, superior cervical ganglia; siRNA; small interfering RNA; TFD, trophic factor deprivation.
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EXPERIMENTAL
For all animal experimentation, Institutional and National
guidelinesforthecareanduseoflaboratoryanimalswasfollowed.
Neuronal hippocampal cultures
Primary cultures of hippocampal neurons were established from
E18 (embryonic day 18) rat pups of pregnant Sprague–Dawley
rats (Charles River Laboratories) or from P1 (postnatal day 1)
mice as described previously [15]. Brieﬂy, hippocampi were
dissected, dissociated by trituration in serum-free medium and
plated on poly-D-lysine (0.1 mg/ml)-coated tissue culture plates.
Neurons were plated in a 1:1 mixture of Eagle’s MEM (minimal
essential medium) and Ham’s F12 (Invitrogen) supplemented
with glucose (6 mg/ml), putrescine (60 μM), progesterone
(20 nM), transferrin (100 μg/ml), selenium (30 nM), penicillin
(0.5 units/ml) and streptomycin (0.5 μg/ml) (Sigma) at a density
of 300000 cells/ml. Cell were incubated at 37◦Ci na5% CO2
atmosphere and treated 7 days post-plating.
Sympathetic neuronal cultures
Primary cultures of dissociated sympathetic neurons were
prepared from the SCG (superior cervical ganglia) of P1 wild-
type or PIDD-null mice [11] as described previously [4]. Brieﬂy,
SCG were removed from the neonates and trypsinized for 45 min
at 37◦C to remove the capsules. Cells were resuspended in RPMI
1640 medium with 10% horse serum supplemented with mouse
NGF (50 ng/ml) and plated on to tissue culture plates coated with
collagen. At 1 day after plating, uridine and 5-ﬂuorodeoxyuridine
(10 μM each) were added to the cultures and left for 4 days to
eliminate non-neuronal cells.
Neuronal PC12 cells
PC12 cells were grown on collagen-coated plates for 7 days in
serum-free RPMI 1640 medium containing NGF (100 ng/ml) as
described previously [13].
siRNA (small interfering RNA) and AS (antisense)-RNA design
siRNAs were designed according to published design guidelines
[16] with dTdT 3
  overhangs. Sequences for the sense strand of
the central 19-nt double-stranded region were: siCaspase-2, 5
 -
GCCAUGCACUCCUGAGUUU-3
 ; siRAIDD, 5
 -CCACAUUC-
AAGAAAUCAAA-3
 ; siPIDD, 5
 -CCUGGGUGAUGCAGAA-
ACU-3
 ; and AS-PIDD, 5
 -AACACUGCAGCCAUCAC-3
 .
siRNA and AS-RNA coupling
siRNA duplexes with a 5
  thiol modiﬁcation on the sense strand
or AS-RNA with a 5
  thiol modiﬁcation were synthesized
and HPLC-puriﬁed (Dharmacon) [17,18]. Annealed siRNA
duplexes or AS-RNA were resuspended in buffer provided by the
manufacturer and treated with an equimolar mixture of TCEP
[tris-(2-carboxyethyl)phosphine] at room temperature (23◦C)
for 1 h. An equimolar ratio of Pen1 (Penetratin1; Q-Biogene)
was added, and the mixture was heated to 65◦C for 15 min and
then incubated at 37◦C for 1 h. The yields of the reactions were
estimated at 90% by SDS/PAGE using SybrGold (Molecular
Probes) (results not shown).
Aβ preparation
Aβ
1–42 peptide was purchased from Dr David Teplow (David
GeffenSchoolofMedicine,UniversityofCaliforniaLosAngeles,
Los Angeles, CA, U.S.A.) and was resuspended in 100% HFIP
(1,1,1,3,3,3 hexaﬂuoro-2-propanol) at a ﬁnal concentration of
1 mM. For complete solubilization, the peptide was homogenized
using a 250 μl Hamilton syringe with a Teﬂon plunger. HFIP was
removed by evaporation in a SpeedVac, Aβ
1–42 was resuspended
at a concentration of 5 mM in DMSO and sonicated in a water
bath sonicator (Branson Ultrasonics, model 3510) for 10 min.
Oligomers were prepared as described previously [19]. Brieﬂy,
Aβ
1–42 was diluted in PBS+1/10 volume of 2% SDS in H2Ot o
400 μM. Aβ was incubated for 24 h at 37◦C and further diluted
to 100 μM in PBS, followed by an 18 h incubation at 37◦C.
NGF deprivation
At 7 days after plating, sympathetic neurons were rinsed three
times in sterile PBS, and then either re-exposed to medium
supplementedwithNGF,ordeprivedofNGFbyapplyingananti-
mouse NGF antibody (Sigma, 1:200). For neuronal PC12 cells,
cells were washed ﬁve times in serum-free medium without NGF
and then either re-exposed to medium with NGF or serum-free
medium without NGF.
Neuronal viability
The number of viable cells was determined by quantifying
the number of intact nuclei as described previously [5,20]. For
hippocampalneurons,culturemediumwasremovedbyaspiration
and 100 μl of CHAPS lysis buffer [150 nM KC1, 50 mM Hepes,
0.1% CHAPS and a protease inhibitor tablet (pH 7.4)] was added
to the well. This solution dissolves cell membranes providing a
suspension of intact nuclei. Intact nuclei were quantiﬁed using
a haemocytometer. Triplicate wells were scored and are reported
as means+ −S.E.M. Signiﬁcance is calculated by Student’s t test.
For sympathethic neurons, each culture was scored as numbers of
living phase-bright neurons counted in the same ﬁeld at various
times. Three replicate cultures were assessed for each condition,
and data are normalized to the number of neurons present in each
culture at the time of Aβ
1–42 addition or NGF deprivation and are
reported as means+ −S.E.M.
mRNA extraction and real-time PCR
RNA was isolated from cultured neurons using TRIzol® reagent.
cDNA was prepared by reverse transcriptase using SuperScript
II and oligo(dT) primer (Invitrogen). Primers were designed to
amplify a 300–400 base region of the targeted mRNA spanning
the siRNA-targeting site for PIDD, RAIDD and CASP2 (HUGO
gene symbol for caspase 2). cDNA was added to a reaction
mixture (OmniMix HS beads; Cepheid) with SYBR Green
(Molecular Probes) together with appropriate primers at 0.5 μM
each. Levels of transcripts were analysed using the Cepheid
SmartCycler(Fisher)followingthemanufacturer’sspeciﬁcations.
RNA controls were used to ensure that ampliﬁcation of products
did not come from genomic DNA. Melting curve analysis was
used to determine the temperature for ﬂuorescence detection.
For each mRNA, quantiﬁcation was made from the linear
portion of the ampliﬁcation curve. TUBB (β-tubulin) and
GAPDH (glyceraldehyde-3-phosphatedehydrogenase)wereused
as internal controls for normalization of the expression of mRNA
levels against PIDD, RAIDD and CASP2.
Western blot analysis
Proteins were electrophoretically separated by SDS/PAGE (12%
gels) and transferred on to a 0.2 μm nitrocellulose membrane
(Whatman) in 2.5 mM Tris/19.2 mM Glycine/20% methanol
transfer buffer. The membrane was blocked in Odyssey blocking
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buffer (LI-COR Biosciences) diluted 1:1 in PBS for 1 h at room
temperature and incubated with primary antibodies overnight at
4◦C, and with secondary antibody [IRdye 800 (1:25000 dilution;
Rockland Immunochemicals) or Alexa Fluor® 680 (1:25000;
Molecular Probes)] for 2 h at room temperature. The membrane
was washed three times in PBST (PBS containing 0.05% Tween
20) followed by a ﬁnal wash in PBS. Bands were visualized
and quantiﬁed using the Odyssey Infrared Imager (LI-COR Bios-
ciences). Primary antibodies used were anti-(caspase 2) (custom-
made [6]), anti-RAIDD (Stressgen) and anti-PIDD (Axxora). As
a loading control the same membranes were incubated with anti-
bodies against α-tubulin (1:10000; Abcam), ERK (extracellular-
signal-regulated kinase) 1 (1:10000; Santa Cruz Biotechnology)
or actin (1:10000; Sigma). Levels of immunopositive bands were
analysed densitometrically using ImageJ (NIH).
Biotin-VAD-FMK (biotin-Val-Ala-DL-Asp-ﬂuoromethylketone)
trapping of active caspases
The biotin-VAD-FMK assay was used to detect the presence
of active caspase 2, as described previously [21]. Brieﬂy, rat
hippocampal neurons or mouse sympathetic neurons were pre-
treatedfor2 hwith50 μMbiotin-VAD-FMK(MPBiomedical)at
37◦C. Cells were treated with 3 μM oligomeric Aβ for the times
indicated and were harvested in CHAPS buffer [150 mM KCl,
50 mM Hepes and 0.1% CHAPS (pH 7.4)] supplemented with
protease inhibitor cocktail tablets (Complete Mini, Roche). Cells
were spun at 15000 g for 10 min at ??◦C and the supernatant
was collected and boiled for 5 min. Streptavidin–agarose beads
were added to the boiled supernatant and incubated in a rotor
overnight at 4 ◦C. Beads were spun at 7500 g for 5 min at 4◦C,
washed ﬁve times with PBS, resuspended in sample buffer [1%
SDS, 3% glycerol and 20 mM Tris/HCl (pH 6.8)] and boiled for
5 min. Beads in sample buffer were spun at 15000 g for 10 min
at 4◦C, supernatant was collected and supplemented with 5%
2-mercaptoethanol and samples were loaded on to a 12% PAGE
gel for Western blot analysis using an afﬁnity-puriﬁed polyclonal
anti-(caspase 2) antibody.
Caspase 2 and RAIDD co-immunoprecipitation
MouseIgGorrabbitIgGmagnetizedbeads(Invitrogen)werepre-
coatedwithananti-RAIDDantibody,anti-CRADD(caspase2and
RIPK1domain-containingadaptorwithDD;Abnova)antibodyor
anti-(caspase 2) (custom-made) antibody respectively for 2 h at
4◦C on a rotator. In total, 2 μg of anti-CRADD antibody or 10 μl
of anti-(caspase 2) antibody was used per 30 μl of beads. Primary
rat hippocampal neurons were treated with Aβ
1–42 (3 μM) for 2 or
4 h.CelllysateswerepreparedusingCHAPSlysisbuffer.Lysates
(70–120 μg)wereloadedontoanti-CRADDantibodypre-coated
beads and incubated overnight at 4◦C on a rotator. Following
overnight incubation the captured proteins were boiled off the
beads at 100◦C for 5 min. The immunoprecipitated samples,
along with inputs, were then subjected to Western blot analysis
using afﬁnity-puriﬁed polyclonal anti-(caspase 2) or monoclonal
anti-CRADD antibodies.
RESULTS
Caspase 2 is activated in neurons by Aβ exposure or NGF
deprivation
Our laboratory and others have previously described that knock
down of caspase 2 protects neurons against Aβ-mediated [5] or
NGFdeprivation-induced[4,6]celldeath.Caspase2isaninitiator
caspase; initiator caspases do not require cleavage for activation
[8]. Thus cleavage is not an accurate read-out for activation. To
measure caspase 2 activity, we have recently adapted the caspase-
afﬁnity ligand method [22] to detect active initiator caspases in
neurons and found that 3 h of Aβ treatment induced caspase
2 activation [21]. To conﬁrm and extend these ﬁndings, we
used this method to examine caspase 2 activity after Aβ and
NGF deprivation [TFD (trophic factor deprivation)]. Primary
neuronal cultures were treated with 50 μM biotin-VAD-FMK
for 2 h and then exposed to death-inducing stimuli, either 3 μM
Aβ for hippocampal cultures or anti-NGF antibody to deplete
NGF from sympathetic neuronal cultures. After 2 h of treatment
with the death stimuli, cultures were harvested and biotin-VAD-
FMK–caspase complexes were isolated and active caspase 2 was
identiﬁedbyWesternblotanalysis(Figure1).Aβ treatmentfor2 h
induced an almost 4-fold increase in caspase 2 activity in primary
hippocampal neurons (Figures 1A and 1B). After 2 h of NGF
withdrawal, caspase 2 activity increased 2-fold in sympathetic
neuronscomparedwithbasallevels(Figures1Cand1D).Western
blot analysis with anti-caspase 9 or anti-caspase 8 antibodies did
notshowactivationofeitherofthesecaspases(resultsnotshown).
We have recently shown that another paradigm of neuronal death
inducesactivecaspase9andcaspase8,supportingthefactthatwe
are able to detect these caspases when they are active [23]. These
results imply that both death stimuli, Aβ and NGF withdrawal,
activate caspase 2, and that caspase 2 is the critical caspase
responsible for neuronal death under these conditions.
These results led us to study the caspase 2 activation complex
in these neurons. The PIDDosome has been proposed to induce
caspase 2 activation [10]. This complex has been proposed to
form by the interaction between caspase 2 and RAIDD via their
CARDandbetweenRAIDDandPIDDviatheirDDs(aschematic
representation of this activation complex, partners and interaction
domains is shown in Figure 2A). We have shown previously
that AS knockdown of caspase 2 protects neurons from Aβ [5]
and from NGF deprivation [6], and that siRNA against RAIDD
protects from NGF deprivation [13]. To more fully determine
the function of the PIDDosome in caspase-2-mediated neuronal
death, we designed siRNA for each component of the complex;
we also used the previously published AS-RNA sequence for
PIDD [24] and linked it to Pen1. These siRNAs and AS-RNA
contain a 5
  thiol modiﬁcation used to link the oligonucleotide via
a disulﬁde bond to Pen1 [17,18] and their knock-down efﬁciency
was tested by Western blot analysis (Figures 2C and 2E) and
by real-time PCR (Figures 2B, 2D, 2F and 2G). All of the
siRNA presented here showed a reduction of at least 50% at
themRNAlevelsand,forcaspase2andRAIDD,anapproximately
70% knock down at the protein level. As expected, siRNA
against caspase 2 did not change the expression level of other
caspases, and siRNA against PIDD or RAIDD did not change
expression levels of any of the caspases (results not shown).
We attempted to measure endogenous PIDD using commercially
available antibodies, but the PIDD antibodies were found to not
be speciﬁc for endogenous PIDD (Supplementary Figure S1 at
http://www.BiochemJ.org/bj/444/bj4440591add.htm).
RAIDD, but not PIDD, is required for caspase-2-dependent
neuronal death
To determine which components of the caspase 2 activation
complex were required for neuronal cell death, we investigated
the role of each component in neuronal survival using the Pen1-
siRNA and Pen1-AS-RNA. We treated hippocampal neurons
with Pen1-siRNA against caspase 2, RAIDD, PIDD (siCasp2,
siRAIDDandsiPIDD)orAS-RNAagainstPIDD(AS-PIDD)and
3 μMA β was added to the neurons. After 24 h of Aβ treatment
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Figure 1 Aβ and NGF deprivation induce active caspase 2 in neurons
(A) Hippocampal neuron cultures were treated with 50μM biotin-VAD-FMK for 2h and then with or without 3 μMA β for an additional 2 h. Active caspase 2 was pulled down using streptavidin
beads and identiﬁed by Western blot analysis with a polyclonal anti-(caspase 2) antibody. Representative blots are shown; the experiments were repeated ﬁve times. (B) Densitometry of relative
caspase 2 activity induced by Aβ treatment from ﬁve independent blots. (C) Sympathetic neuron cultures were treated with 50μM biotin-VAD-FMK for 2h and then with or without NGF deprivation
(TFD) for an additional 2 h. Active caspase 2 was pulled down using streptavidin beads and identiﬁed by Western blot analysis with a polyclonal anti-(caspase 2) antibody. Representative blots are
shown; the experiments were repeated three times. (D) Densitometry of relative caspase 2 activity induced by TFD from three independent blots. Co, control.
Figure 2 Potential components of the caspase 2 activation complex
(A) Schematic diagram of components of the PIDDosome: caspase 2, RAIDD and PIDD. Potential interaction domains (CARD for caspase 2 and RAIDD, and DD for RAIDD and PIDD) are indicated.
(B) Hippocampal neuron cultures were treated with Pen1-siCasp2 (80nM) for 6 h and analysed by quantitative PCR for CASP2 expression, mRNA was normalized to TUBB mRNA expression.
n=3.(C)HippocampalneuronculturesweretreatedwithPen1-siCasp2(80nM)for6handanalysedbyWesternblottingforcaspase2proteinexpression,α-tubulinwasusedasaloadingcontrol.
Representative blots are shown; the experiments were repeated three times. (D) Hippocampal neuron cultures were treated with Pen1-siRAIDD (80nM) for 6h and analysed by quantitative PCR for
RAIDD expression, mRNA was normalized to TUBB mRNA expression. n=3. (E) Hippocampal neuron cultures were treated with Pen1-siRAIDD (80nM) for 5 h and analysed by Western blotting
for RAIDD protein expression, α-tubulin was used as a loading control. Representative blots are shown; the experiments were repeated three times. (F) Hippocampal neuron cultures were treated
with Pen1-siPIDD (80nM) for 6h and analysed by quantitative PCR for PIDD expression, mRNA was normalized to TUBB mRNA expression. n=3. (G) Hippocampal neuron cultures were
treated with Pen1-AS-PIDD (80nM) for 6 h and analysed by quantitative PCR for PIDD expression, mRNA was normalized to TUBB mRNA expression. n=3.
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Figure 3 RAIDD, not PIDD, is required for caspase-2-dependent neuronal death
(A) Hippocampal neuron cultures were treated for 2 h with or without the indicated Pen1-oligonucleotides (80nM) and then treated with or without 3 μMA β for 24h. Relative neuronal survival
was quantiﬁed and is expressed as the percentage survival relative to control cultures, each point was assayed in triplicate and the experiment was repeated three times. (B) Sympathetic neuron
cultures were treated for 2 h with the indicated Pen1-oligonucleotides (80nM) and then with or without NGF deprivation (TFD) for 24h. Relative neuronal survival was quantiﬁed after 24h TFD and
is expressed as the percentage of neurons remaining relative to the initial number of neurons in each culture, each point was assayed in triplicate and the experiment was repeated three times.
Figure 4 RAIDD is required for caspase 2 activation, PIDD is not
(A) Hippocampal neuron cultures were treated with or without Pen1-siRAIDD (80nM) for 1 h and then with biotin-VAD-FMK (50μM) for 2h prior to Aβ treatment and exposure to 3μMA β or
vehicle for 2h. Active caspase 2 was pulled down using streptavidin beads and identiﬁed by Western blot analysis with a polyclonal anti-(caspase 2) antibody. Representative blots are shown; the
experiments were repeated three times. (B) Densitometry of relative caspase 2 activity induced by Aβ treatment with and without Pen1-siRAIDD from three independent blots. (C) Hippocampal
neuron cultures were treated with or without Pen1-siPIDD (80nM) for 1h, then with biotin-VAD-FMK (50μM) for 2h, and then with or without 3 μMA β for an additional 2 h. Active caspase 2 was
pulled down using streptavidin beads and identiﬁed by Western blot analysis with a polyclonal anti-(caspase 2) antibody. Representative blots are shown; the experiments were repeated three times.
(D) Densitometry of relative caspase 2 activity induced by Aβ treatment with and without Pen1-siRAIDD from three independent blots. Co, control.
neuronal survival was quantiﬁed. In order to evaluate off-target
effectsassociatedwiththepresenceofthesiRNA,asetofneurons
were left untreated (control), whereas another set of sister
neurons were treated exclusively with siRNA. The addition of
3 μMA β to the cultures induced, over a 24 h period, 52% cell
death compared with the control untreated neurons (Figure 3A).
Although the presence of siCasp2 or siRAIDD totally prevented
Aβ-induced cell death, siPIDD or AS-PIDD did not abrogate Aβ
toxicity. The efﬁcacy of siCasp2 validates the siRNA approach
for these studies as it conﬁrms the requirement for caspase 2 that
we have previously shown using either AS knockdown or caspase
2-null neurons [5]. The effect of siRAIDD suggests a critical role
for RAIDD in Aβ-induced toxicity. None of the siRNAs used in
the present study were toxic since the cultures treated only with
siRNA showed survival rates similar to those found in control
neurons.
Our previous studies investigating the function of RAIDD in
NGF-deprivation-induced neuronal death used a different siRNA
sequence and did not use Pen1 to deliver the siRNA [13].
To conﬁrm that the Pen1-siRAIDD was also effective against
NGF deprivation, sympathetic neurons were treated with each
individual Pen1-siRNA independently or in combination with
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NGF deprivation, and neuronal survival was measured 24 h
after NGF deprivation. Similar to the results found for Aβ, NGF
deprivation killed over 50% of the neurons and, as expected,
siCasp2 and siRAIDD both prevented NGF-deprivation-induced
neuronal death. In contrast, down-regulation of PIDD via siRNA
or AS-RNA had no effect. None of the siRNA used were toxic
to the sympathetic neurons (Figure 3B). These data conﬁrm our
previous data and, taken together, show that RAIDD, and not
PIDD, is the critical adaptor molecule responsible for executing
caspase-2-mediated neuronal death.
RAIDD is necessary for the activation of caspase 2
Having shown that RAIDD is required for caspase-2-dependent
neuronal death, we now tested whether RAIDD is required
for induction of caspase 2 activity. In order to address
this question, primary hippocampal neurons were pre-treated
with Pen1-siRAIDD for 1 h, treated with 50 μM biotin-VAD-
FMK for 2 h prior to Aβ treatment, and then exposed to
3 μMA β for 2 h. In a parallel experiment, sister neurons were
treated with vehicle (control) or treated with Pen1-siRAIDD
or Aβ alone. Samples were harvested and biotin-VAD-FMK–
caspase complexes were isolated to detect levels of active
caspase 2. Aβ induced an almost a 4-fold increase in the levels
of active caspase 2 compared with control cells (Figures 4A
and 4B). Pre-treatment of neurons with Pen1-siRAIDD totally
preventedAβ-inducedcaspase2activation.TheadditionofPen1-
siRAIDD alone did not activate caspase 2. This demonstrates that
RAIDDisnecessaryforcaspase2activationinneurons.Thesame
blot was re-probed for caspase 9 and for caspase 8 and there was
no activation of either of these caspases (results not shown).
PIDD is not required for caspase 2 activation
Todeterminewhether PIDDhasarolein theactivationofcaspase
2, we treated hippocampal neurons with or without Pen1-siPIDD
for 1 h, and then added biotin-VAD-FMK for 2 h followed by the
addition of Aβ. After a 2 h incubation with Aβ, samples were
harvested, biotin-VAD-FMK–caspase complexes were isolated
and levels of active caspase 2 were determined by Western blot
analysis(Figures4Cand4D).Inaccordancewithpreviousresults,
Aβ resulted in the activation of caspase 2 by almost 4-fold,
and Pen1-siPIDD-treated cultures showed similar levels of active
caspase 2 to those detected in control cultures. However, the
presence of Pen1-siPIDD in conjunction with Aβ did not prevent
the activation of caspase 2, demonstrating that the presence of
PIDD is not necessary for the activation of caspase 2.
PIDD-null neurons undergo Aβ and NGF-deprivation-mediated
caspase-2-dependent death
Because both PIDD and RAIDD have been proposed to be part of
thecaspase2activationcomplex,andwehaveshownthatPIDDis
not essential for caspase 2 activation, we studied whether PIDD-
null primary neurons are sensitive to caspase-2-dependent death
stimuli, such as Aβ or NGF deprivation. Primary sympathetic
neurons from PIDD-null mice were treated with Pen1-siRNA
againstcaspase2orRAIDDalone,orincombinationwithAβ,and
neuronsweresubjectedtosurvivalanalysis24 haftertheaddition
of Aβ into the cultures (Figure 5A). PIDD-null neurons were as
sensitive to Aβ as wild-type neurons, showing an approximately
50%neuronalsurvivalafter24 h.Asfoundforwild-typeneurons,
PIDD-null neurons were totally protected against Aβ toxicity
Figure 5 Caspase 2 and RAIDD execute Aβ- or NGF-deprivation-induced
death of PIDD-null neurons
(A) Sympathetic neuron cultures from PIDD-null mice were cultured with the indicated
Pen1-siRNA (80nM) and then treated with or without 3 μMA β for 24h. Relative neuronal
survival was quantiﬁed and is expressed as the percentage survival relative to control cultures.
Eachpointwasassayedintriplicateandtheexperimentwasrepeatedthreetimes.(B)Sympathetic
neuronculturesfromPIDD-nullmiceweretreatedfor2hwiththeindicatedPen1-siRNA(80nM)
andthenwithorwithoutNGFdeprivation(TFD)for24h.Relativeneuronalsurvivalwasquantiﬁed
after 24h TFD and is expressed as the percentage of neurons remaining relative to the initial
number of neuronsin each culture. Each point was assayed in triplicate and the experiment was
repeated three times.
when treated with either Pen1-siCasp2 or Pen1-siRAIDD, each
treatment yielding 100% survival of neurons.
To determine the requirement for PIDD in NGF-deprivation-
mediated death, PIDD-null primary sympathetic neurons were
cultured and pre-treated for 1 h with Pen1-siRNA against caspase
2orRAIDD,andthensubjectedtoNGFdeprivation.Survivalwas
quantiﬁed after 1 day of treatment (Figure 5B). Neurons lacking
PIDD were as sensitive as wild-type neurons to NGF deprivation,
and siCasp2 and siRAIDD each protected neurons against NGF-
deprivation-mediated apoptosis. These results demonstrate that
PIDD-nullneuronscanundergocaspase-2-dependentdeathunder
the conditions studied, and that RAIDD is an essential modulator
of caspase-2-dependent death. To conﬁrm that there is induc-
tion of caspase 2 activity in PIDD-null neurons, PIDD-null neur-
ons were pre-treated for 2 h with biotin-VAD-FMK followed by a
2 hdepletionofNGF.Biotin-VAD-FML–caspasecomplexeswere
isolated and analysed by Western blotting to detect active caspase
2. NGF depletion for 2 h was able to activate caspase 2 in PIDD-
nullneurons(Figure6),inlevelscomparablewiththoseseenwith
wild-typeneurons(Figure1).Theseobservationsdemonstratethat
the caspase 2 machinery is intact in the absence of PIDD.
Aβ and NGF deprivation induce formation of a complex of RAIDD
and caspase 2 in wild-type and PIDD-null neurons
To further study the activation complex for caspase 2,
we performed co-immunoprecipitation studies. Hippocampal
neurons were treated with Aβ for 1 h, immunoprecipitated with
an anti-RAIDD antibody and then immunoblotted for caspase
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Figure 6 NGF deprivation induces caspase 2 activation in PIDD-null
neurons
(A)SympatheticneuronculturesfromPIDD-nullmiceweretreatedwith50μMbiotin-VAD-FMK
for2handthenwithorwithoutNGFdeprivation(TFD)foranadditional2h.Activecaspase2was
pulled down using streptavidin beads and identiﬁed by Western blot analysis with a polyclonal
anti-(caspase 2) antibody. Representative blots are shown; the experiments were repeated three
times. Co, control. (B) Densitometry of relative caspase 2 activity induced by TFD from three
independent blots.
2 (Figure 7A). There was a more than 8-fold increase in
caspase 2 pulled down by the anti-RAIDD antibody following
treatment with Aβ for 1 h. To evaluate the requirement for PIDD
in formation of this complex, we used hippocampal neurons from
PIDD-null mice and showed that Aβ treatment induced a similar
induction of the caspase 2–RAIDD interaction (Figure 7B). To
determine whether TFD also induced formation of a caspase 2–
RAIDD complex, we used neuronal PC12 cells, a model that we
have previously shown requires caspase 2 to execute death [6].
We used this model because the sympathetic neuron cultures do
not provide enough protein for co-immunoprecipitation analysis.
TFD induced formation of the caspase 2–RAIDD complex
(Figure7C).InFigure7(D)weshowthat,inhippocampalneurons
treated with Aβ, immunoprecipitation with caspase 2 pulls down
RAIDD, at a level similar to the reverse immunoprecipitations.
There is no increase in RAIDD mRNA (Figure 7E) or protein
expression (Figure 7F) in response to Aβ treatment, suggesting
thatitistheco-localizationofcaspase2andRAIDDthatiscritical.
DISCUSSION
ThepresentstudyshowsthatbothAβ andNGFdeprivationinduce
caspase 2 activity and caspase-2-dependent neuronal death. We
also show that RAIDD is necessary for caspase 2 activity and
neuronal death, but PIDD is not necessary. We provide data
showing that, in neurons, Aβ treatment induces the formation
of a complex containing caspase 2 and RAIDD. Our previous
studies have shown the functional requirement for caspase 2 in
two paradigms of neuronal death, Aβ [5] and NGF deprivation
[4,6]. We now extend those previous studies to the detection of
caspase2activityafterbothofthesedeathstimuli.Theapproachto
measuring caspase activity is one that has evolved over the years.
Cleavage has been used as an indicator of caspase activation for
both effector and initiator caspases. However, it is now clear that
initiatorcaspasesdonotrequirecleavageforactivation,activation
occurs via proximity-induced dimerization [8]. This activation
may be followed by autoprocessing, which can enhance caspase
activity, as shown for caspase 8 [25,26], or have little effect
on caspase activity, as shown for caspase 9 [27]. However, the
critical step in activation of caspases with long pro-domains is
dimerization, and this is effected through interaction with speciﬁc
adaptor proteins. Since cleavage is not necessary for activation,
assays that measure cleavage do not present a clear measure of
initiator caspase activation. In support of this, studies of PIDD-
null cells showed that caspase 3 or caspase 7 is responsible for
the cleavage of caspase 2, which is not an activation step [11].
Another frequently used measure of caspase activity uses peptide
substrates to measure activity in cell lysates. For caspase 2 the
substrate is VDVAD (Val-Asp-Val-Ala-Asp), but this substrate
is a better substrate for caspase 3 than for caspase 2, thus it is
alsoaninadequatemeasureofcaspase2activity[28].Forinitiator
caspases a method has been adapted that uses a caspase-afﬁnity
ligand, biotin-VAD-FMK, to capture active caspases. By pre-
treating cells with this reagent the proximal caspase(s) in the
death pathway will be captured and all subsequent effects of
these caspases in the cells will be inhibited. This approach has
been used in non-neuronal cells for a variety of death paradigms
[22]. We have previously adapted this for use in primary neurons
[21] and in the central nervous system in vivo [23]. Our previous
studies of Aβ showed that active caspase 2 could be detected 3 h
after treatment of hippocampal cultures with Aβ.W en o ws h o w
that caspase 2 is active within 2 h of Aβ treatment, and that NGF
deprivationalsoinducesactivecaspase2within2 hofdeprivation.
The induction of caspase 2 activity complements our studies that
show the functional requirement for caspase 2 in these paradigms
[4–6].
The activation complex of caspase 2 is also unknown. Since
we have now shown that both Aβ and NGF deprivation induce
caspase 2 activity and require caspase 2 to execute death,
we used several approaches to study the requirement for the
PIDDosome to activate caspase 2 in neurons. For each member
of the PIDDosome we used Pen1-siRNA to achieve signiﬁcant
knockdown of expression of the targeted mRNA/protein. Pen1
provides facilitated non-toxic delivery of siRNA to neurons at a
high efﬁciency. We have previously shown that transfection of
siRNA using Lipofectamine
TM induced more than 50% death in
neuronal cultures [18]. Since we are studying cell death mech-
anisms it is critical that we are not inducing death by means other
than the death stimuli under study. Our previous work has shown
that RAIDD is required for NGF-deprivation-mediated death of
neurons,butwedidnotexaminetheeffectofdepletionofRAIDD
on caspase 2 activity in those studies [13]. In the present study we
show that RAIDD is required for induction of caspase 2 activity
and for execution of Aβ and NGF deprivation death, thus also
extending the requirement for RAIDD to the Aβ paradigm. We
also show that a complex of caspase 2 and RAIDD is formed in
neurons treated with Aβ or with NGF deprivation.
For PIDD we used multiple approaches to determine its
function in these paradigms. An AS-RNA sequence had been
used previously by another group [24] and we used this sequence
linked to Pen1. We also used an siRNA to knockdown PIDD
and achieved signiﬁcant knockdown of mRNA, but could not
measureproteinbecausewefoundthatthecommercialantibodies
availabledidnotdetectendogenousPIDD,sincethesameproteins
were detected in wild-type and PIDD-null brains (Supplementary
Figure S1). However, the PIDD-null neurons provided a third
approachtodeterminingwhetherPIDDwasrequiredforinduction
of caspase 2 activity or for execution of Aβ- or NGF-deprivation-
mediated death. All of these approaches showed that PIDD was
notessentialforcaspase-2-mediateddeath.Aβ inducedformation
of a caspase 2–RAIDD complex in PIDD-null neurons. Active
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Figure 7 A complex of caspase 2 and RAIDD is induced by Aβ or TFD treatment
(A) Hippocampal neurons were treated with 3μMA β for 1h and harvested for immunoprecipitation with an anti-RAIDD antibody followed by immunoblotting for caspase 2. Input samples were
immunoblotted for caspase 2 and ERK. Representative blots are shown; the experiments were repeated three times. Densitometry was used to determine the relative amount of caspase 2 pulled down
with the anti-RAIDD antibody. (B) Hippocampal neurons from PIDD-null mice were treated with 3μMA β for 4 h and harvested for immunoprecipitation with an anti-RAIDD antibody followed by
immunoblotting for caspase 2. Input samples were immunoblotted for caspase 2 and actin. Representative blots are shown; the experiments were repeated three times. Densitometry was used to
determine the relative amount of caspase 2 pulled down with the anti-RAIDD antibody. (C) Neuronal PC12 cells were subjected to TFD for 4h and and harvested for immunoprecipitation with an
anti-RAIDD antibody followed by immunoblotting for caspase 2. Input samples were immunoblotted for caspase 2 and ERK. Representative blots are shown; the experiments were repeated three
times. Densitometry was used to determine the relative amount of caspase 2 pulled down with the anti-RAIDD antibody. (D) Hippocampal neurons were treated with 3μMA β for 4 h and harvested
for immunoprecipitation with an anti-(caspase 2) antibody followed by immunoblotting for RAIDD. Input samples were immunoblotted for RAIDD and ERK. Representative blots are shown; the
experimentswererepeatedthreetimes.DensitometrywasusedtodeterminetherelativeamountofRAIDDpulleddownwiththeanti-(caspase2)antibody. (E)Sisterculturesweretreatedasdescribed
in (A) and RNA was isolated and analysed by quantitative PCR for RAIDD expression, mRNA was normalized to TUBB mRNA expression. n=3. (F) Sister cultures were treated as described in
(A) and immunoblotted for RAIDD and ERK. Representative blots are shown; the experiments were repeated three times. Densitometry was used to determine the relative amount of RAIDD. IP,
immunoprecipitation; WB, Western blot.
caspase 2 was induced in neurons in which PIDD was knocked
down or knocked out. PIDD-null neurons died in response to Aβ
or NGF deprivation, and death was abrogated by caspase 2 or
RAIDD knockdown.
The requirement for RAIDD in various paradigms of cell
death has not been fully delineated. Overexpression of PIDD
induces cleavage of caspase 2 and cell death [10]. This death was
shown to require RAIDD, but to be only partially dependent on
caspase 2 expression [29]. Assay of caspase 2 activity showed
that PIDD overexpression induced caspase 2 activity, but not as
robustly as overexpression of RAIDD [30]. These results suggest
that overexpression of PIDD does require RAIDD and activates
caspase 2. Another death paradigm shown to require RAIDD
is heat-shock-induced death. In a series of studies the Green
laboratory has shown that heat-shock induces caspase 2 activity
and requires RAIDD to execute death [22,30]. Other groups have
shown for multiple death stimuli that neither RAIDD nor PIDD
were required for a variety of death stimuli in non-neuronal cells
[11,12]; however, these studies did not show that caspase 2 is
required for these death stimuli. As noted above, caspase 2 has
been implicated as functioning in several death paradigms on the
basis of data showing caspase 2 cleavage or utilizing VDVAD to
measure or inhibit caspase 2. However, in the absence of appro-
priate measures of caspase 2 activity and of speciﬁc inhibition
of caspase 2, it is not evident that these death stimuli actually
requirecaspase2,andthusstudiesofthePIDDosomecomplexare
not revealing without deﬁnitive proof that caspase 2 is executing
death. In the present study we have utilized a molecular approach
todeterminethatcaspase2indeedactsasaneuronalexecutionerin
these models, and we also have biochemically measured caspase
2 activity. Our results may suggest that there is a neuron-speciﬁc
activation complex for caspase 2 which contains RAIDD.
Taken together, the results of the present study show that both
Aβ and NGF deprivation induce active caspase 2 in neurons and
that RAIDD is required for execution of death by these stimuli,
whereasPIDDisnot.ThustheentirePIDDosomeisnotnecessary
for caspase 2 activity in neurons, whereas caspase 2 and RAIDD
are essential and do form a complex when exposed to the death
stimulus. Whether another protein is also part of the caspase 2
activation complex in neurons remains to be determined.
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Neuronal caspase 2 activity and function requires RAIDD, but not PIDD
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Figure S1 Commercial antibodies against PIDD are not speciﬁc
Brains were harvested from newborn wild-type (WT), PIDD-null (PIDDKO) and caspase 2-null (C2KO) mice and protein lysates were analysed by Western blotting using commercial antibodies to
detect PIDD. The size of full-length PIDD (83kDa) is indicated on each blot with a black bar. PIDD-C and PIDD-CC are 50kDa and 37kDa respectively. MWM, molecular mass marker. (A) Alexis
AL233 (Als-210-920) should detect full-length PIDD, and PIDD-C and PIDD-CC. (B) Alexis Anto-1 (Alx-804-837) should detect full-length PIDD, and PIDD-C and PIDD-CC. (C)S - 1 7( S a n t aC r u z
Biotechnology; sc-32161) should detect full-length PIDD. (D) H-300 (Santa Cruz Biotechnology; sc-67032) should detect full-length PIDD, and PIDD-C and PIDD-CC.
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